Last reviewed · How we verify

Albumin-bound Paclitaxel plus S-1

Huazhong University of Science and Technology · Phase 3 active Small molecule

Albumin-bound Paclitaxel plus S-1 is a Combination chemotherapy (taxane + fluoropyrimidine) Small molecule drug developed by Huazhong University of Science and Technology. It is currently in Phase 3 development for Gastric cancer (phase 3 investigation), Potentially other solid tumors (investigational).

Albumin-bound paclitaxel inhibits microtubule depolymerization to arrest cell cycle, while S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase to disrupt DNA synthesis, together providing synergistic cytotoxic effects.

Albumin-bound paclitaxel inhibits microtubule depolymerization to arrest cell cycle, while S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase to disrupt DNA synthesis, together providing synergistic cytotoxic effects. Used for Gastric cancer (phase 3 investigation), Potentially other solid tumors (investigational).

At a glance

Generic nameAlbumin-bound Paclitaxel plus S-1
SponsorHuazhong University of Science and Technology
Drug classCombination chemotherapy (taxane + fluoropyrimidine)
TargetMicrotubules (paclitaxel); Thymidylate synthase (S-1)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Albumin-bound paclitaxel (nab-paclitaxel) is a taxane that stabilizes microtubules and prevents their disassembly, leading to mitotic arrest and apoptosis in cancer cells. S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and incorporates into DNA/RNA, disrupting nucleotide synthesis. The combination leverages complementary mechanisms of action to enhance antitumor activity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Albumin-bound Paclitaxel plus S-1

What is Albumin-bound Paclitaxel plus S-1?

Albumin-bound Paclitaxel plus S-1 is a Combination chemotherapy (taxane + fluoropyrimidine) drug developed by Huazhong University of Science and Technology, indicated for Gastric cancer (phase 3 investigation), Potentially other solid tumors (investigational).

How does Albumin-bound Paclitaxel plus S-1 work?

Albumin-bound paclitaxel inhibits microtubule depolymerization to arrest cell cycle, while S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase to disrupt DNA synthesis, together providing synergistic cytotoxic effects.

What is Albumin-bound Paclitaxel plus S-1 used for?

Albumin-bound Paclitaxel plus S-1 is indicated for Gastric cancer (phase 3 investigation), Potentially other solid tumors (investigational).

Who makes Albumin-bound Paclitaxel plus S-1?

Albumin-bound Paclitaxel plus S-1 is developed by Huazhong University of Science and Technology (see full Huazhong University of Science and Technology pipeline at /company/huazhong-university-of-science-and-technology).

What drug class is Albumin-bound Paclitaxel plus S-1 in?

Albumin-bound Paclitaxel plus S-1 belongs to the Combination chemotherapy (taxane + fluoropyrimidine) class. See all Combination chemotherapy (taxane + fluoropyrimidine) drugs at /class/combination-chemotherapy-taxane-fluoropyrimidine.

What development phase is Albumin-bound Paclitaxel plus S-1 in?

Albumin-bound Paclitaxel plus S-1 is in Phase 3.

What are the side effects of Albumin-bound Paclitaxel plus S-1?

Common side effects of Albumin-bound Paclitaxel plus S-1 include Neutropenia, Peripheral neuropathy, Anemia, Thrombocytopenia, Nausea/vomiting, Diarrhea.

What does Albumin-bound Paclitaxel plus S-1 target?

Albumin-bound Paclitaxel plus S-1 targets Microtubules (paclitaxel); Thymidylate synthase (S-1) and is a Combination chemotherapy (taxane + fluoropyrimidine).

Related